Meta-Analysis and Cost-Effectiveness Analysis of Insulin Glargine 100 U/mL Versus Insulin Degludec for the Treatment of Type 2 Diabetes in China
Crossref DOI link: https://doi.org/10.1007/s13300-019-00683-2
Published Online: 2019-09-03
Published Print: 2019-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Su, Wen
Li, Chaoyun
Zhang, Lei
Lin, Ziyi
Tan, Jun
Xuan, Jianwei
Funding for this research was provided by:
Sanofi China Investment Company
Text and Data Mining valid from 2019-09-03
Version of Record valid from 2019-09-03
Article History
Received: 1 April 2019
First Online: 3 September 2019